Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 21;14(16):1824.
doi: 10.3390/diagnostics14161824.

Kidney Dysfunction, Hepatic Impairment, and Lipid Metabolism Abnormalities in Patients with Precapillary Pulmonary Hypertension

Dragos Gabriel Iancu  1   2   3 , Andreea Varga  3   4 , Liviu Cristescu  1   3 , Robert Adrian Dumbrava  1   2 , Florin Stoica  1   2 , Diana Andreea Moldovan  1   3   5 , Radu Adrian Suteu  5 , Ioan Tilea  3   4
Affiliations

Kidney Dysfunction, Hepatic Impairment, and Lipid Metabolism Abnormalities in Patients with Precapillary Pulmonary Hypertension

Dragos Gabriel Iancu et al. Diagnostics (Basel). .

Abstract

Background: Pulmonary hypertension (PH) is a global health issue that has profound medical and research implications.

Methods: This retrospective study examined changes in renal and liver function, as well as lipid metabolism, over a 12-month period in 49 adult patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). All cases were admitted, managed, and followed up with in the PH Center, County Emergency Clinical Hospital of Targu Mures, Romania.

Results: Kidney dysfunction was observed in 12.24% of cases at baseline, decreasing to 8.16% at 12 months, and CTEPH patients were more affected. In particular, CTEPH patients exhibited an improvement in renal function, confirmed by an increase in their glomerular filtration rates. Hepatic impairment was present in 57.14% of subjects at baseline, declining to 42.86% at 12 months, with significant improvements noted in the PAH group. Lipid metabolic dysregulations were experienced by 22.45% of all patients at baseline, decreasing to 16.33% at 6 months, with a slow elevation to 24.49% at 12 months, but with no statistically significant differences. Pharmacological regimens were adjusted in accordance with the PH groups, a patient's functional and clinical response, and laboratory tests.

Conclusions: Our results demonstrate the multi-organ damage in PH and the importance of individualized treatment approaches.

Keywords: chronic thromboembolic pulmonary hypertension; hepatic impairment; kidney dysfunction; lipid metabolism abnormalities; pulmonary arterial hypertension.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
A frequency bar graph depicting the World Health Organization (WHO) functional class values within the PAH and CTEPH groups is illustrated.
Figure 2
Figure 2
Values of the 6MWT comparing baseline (0), follow-up at 6 months (1), and follow-up at 12 months (2) within the PAH (a) and CTEPH (b) groups, with the exposure of individual values for each moment.
Figure 3
Figure 3
A comparative illustration of the median NT-proBNP values accompanied by the interquartile range (IQR) for the three studied time points within the PAH (a) and CTEPH (b) groups. 0, baseline; 1, follow-up at 6 months; 2, follow-up at 12 months.
See this image and copyright information in PMC

References

    1. Humbert M., Kovacs G., Hoeper M.M., Badagliacca R., Berger R.M.F., Brida M., Carlsen J., Coats A.J.S., Escribano-Subias P., Ferrari P., et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 2022;43:3618–3731. doi: 10.1093/eurheartj/ehac237. - DOI - PubMed
    1. Simonneau G., Montani D., Celermajer D.S., Denton C.P., Gatzoulis M.A., Krowka M., Williams P.G., Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. 2019;53:1801913. doi: 10.1183/13993003.01913-2018. - DOI - PMC - PubMed
    1. Hoeper M.M., Humbert M., Souza R., Idrees M., Kawut S.M., Sliwa-Hahnle K., Jing Z.C., Gibbs J.S. A global view of pulmonary hypertension. Lancet Respir. Med. 2016;4:306–322. doi: 10.1016/S2213-2600(15)00543-3. - DOI - PubMed
    1. Frost A., Badesch D., Gibbs J.S.R., Gopalan D., Khanna D., Manes A., Oudiz R., Satoh T., Torres F., Torbicki A. Diagnosis of pulmonary hypertension. Eur. Respir. J. 2019;53:1801904. doi: 10.1183/13993003.01904-2018. - DOI - PMC - PubMed
    1. Nickel N.P., Galura G.M., Zuckerman M.J., Hakim M.N., Alkhateeb H., Mukherjee D., Austin E.D., Heresi G.A. Liver abnormalities in pulmonary arterial hypertension. Pulm. Circ. 2021;11:20458940211054304. doi: 10.1177/20458940211054304. - DOI - PMC - PubMed

LinkOut - more resources